SUBSCRIBE
SUBSCRIBE

Opus Genetics

NEWS
Business
Spark Founders Launch Opus Genetics to Tackle Rare Forms of Blindness
The startup’s initial focus will be on rare blindness conditions affecting pediatric patients.
September 22, 2021
 · 
2 min read
 · 
Alex Keown
JOBS
IN THE PRESS
Press Releases
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
July 24, 2025
 · 
6 min read
Press Releases
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 3, 2025
July 4, 2025
 · 
2 min read
Press Releases
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
June 26, 2025
 · 
8 min read
Press Releases
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
June 23, 2025
 · 
5 min read
Press Releases
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
June 2, 2025
 · 
13 min read
Press Releases
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
May 15, 2025
 · 
19 min read
Press Releases
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
May 12, 2025
 · 
10 min read
Press Releases
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
May 7, 2025
 · 
11 min read
Press Releases
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
May 5, 2025
 · 
13 min read
Press Releases
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
April 9, 2025
 · 
13 min read
Load More